Amgen (AMGN) Change in Receivables (2009 - 2026)

Amgen has reported Change in Receivables for 18 years, with the latest figure at $1.1 billion in Q2 2026.

• On a quarterly basis, Change in Receivables rose 112.23% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $1.5 billion, a 9.4% decrease from a year earlier, with the FY2025 full-year figure at $2.7 billion, up 706.8% from the prior year.
• Change in Receivables was $1.1 billion for Q2 2026 at Amgen, up from -$413.0 million in the prior quarter.
• The five-year high for Change in Receivables was $1.3 billion in Q1 2025, with the low at -$486.0 million in Q1 2024.
• Average Change in Receivables over 5 years is $259.8 million, with a median of $187.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Change in Receivables surged 451.79% in 2022, then tumbled 437.5% in 2024.
• Over 5 years, Change in Receivables stood at $180.0 million in 2022, then jumped by 140.56% to $433.0 million in 2023, then tumbled by 209.24% to -$473.0 million in 2024, then soared by 327.27% to $1.1 billion in 2025, then gained by 1.67% to $1.1 billion in 2026.
• The last three Change in Receivables figures came in at $1.1 billion (Q2 2026), -$413.0 million (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.